Due to health issues, this site is no longer maintained and will be shut down shortly.

GY:EVT Evotec SE

Evotec SE provides drug discovery and development solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and not-for-profit organizations worldwide. The company's EVT Execute segment offers drug discovery services, such as target identification and validation, hit identification, sample management, chemistry, drug metabolism and pharmacokinetics, research informatics and in silico drug discovery, proteomics and metabolomics, bio-reagents, in vitro biology, in vivo pharmacology, biomarkers, and antibody discovery; INDiGO, a program for accelerating drug development; integrated chemistry, manufacturing, and control services; integrated drug discovery services; and integrated pre-clinical development services. Its EVT Innovate segment is involved in developing drug discovery projects, assets, and platforms. The company's portfolio of research and development programs include diabetes and diabetic complications, fibrosis, immunology, infectious and inflammatory diseases, kidney and liver diseases, oncological and rare diseases, pain, respiratory diseases, and women's health. Evotec SE has a strategic collaboration with the University Hospital Erlangen regarding molecular analyses of biospecimens from the German chronic kidney disease cohort study. The company was founded in 1993 and is headquartered in Hamburg, Germany.This company has ADRs that trade in the U.S. as the symbol EVO.

17.69 EUR
As of 03/22/2023

Security Information
Category1:  Global Equity
Category2:  Comon stocks
Category3:  Developed markets ex-US
GICS sector:  Health Care
Index country:  Germany
Country of incorporation:  Germany
IPO date:  11/10/1999
Stock exchange:    Deutsche Boerse Xetra
Exchange country:   Germany
Market cap:   4,384,895,488 EUR
Current dividend yield:   0.00%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy